Open access · CC-BY
via OpenAlex
Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐XL–BAX interaction
Tareq Saleh, Valerie J. Carpenter, Liliya Tyutyunyk‐Massey, Graeme F. Murray, Joel D. Leverson, Andrew James Souers, Moureq Rashed Alotaibi, Anthony C. Faber, Jason C Reed, Hisashi Harada, David A. Gewirtz
Molecular Oncology · 2020 · ▲ 197 citations
Abstract
Tumor cells undergo senescence(definition) in response to both conventional and targeted cancer therapies. The induction of senescence in response to cancer therapy can contribute to unfavorable patient outcomes, potentially including disease relapse. This possibiliy is supported by our findings that tumor cells induced into senescence by doxorubicin or etoposide can give rise to viable tumors in vivo. We further demonstrate sensitivity of these senescent tumor cells to the senolytic ABT‐263 (navitoclax), therefore providing a “two‐hit” approach to eliminate senescent tumor cells that persist after exposure to chemotherapy or radiation. The sequential combination of therapy‐induced senescence and ABT‐263 could shift the response to therapy toward apoptosis by interfering with the interaction between BCL‐XL and BAX. The administration of ABT‐263 after either etoposide or doxorubicin also resulted in marked, prolonged tumor suppression in tumor‐bearing animals. These findings support the premise that senolytic therapy following conventional cancer therapy may improve therapeutic outcomes and delay disease recurrence.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/1878-0261.12761
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Saleh, T., Carpenter, V.J., Tyutyunyk‐Massey, L., Murray, G.F., Leverson, J.D., Souers, A.J., Alotaibi, M.R., Faber, A.C., Reed, J.C., Harada, H., & Gewirtz, D.A. (2020). Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐XL–BAX interaction. <em>Molecular Oncology</em>. https://doi.org/10.1002/1878-0261.12761
Vancouver
Saleh T, Carpenter VJ, Tyutyunyk‐Massey L, Murray GF, Leverson JD, Souers AJ, et al. Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐XL–BAX interaction. Molecular Oncology. 2020. doi:10.1002/1878-0261.12761.
BibTeX
@article{tareq2020Cleara,
title = {Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐XL–BAX interaction},
author = {Tareq Saleh and Valerie J. Carpenter and Liliya Tyutyunyk‐Massey and Graeme F. Murray and Joel D. Leverson and Andrew James Souers and Moureq Rashed Alotaibi and Anthony C. Faber and Jason C Reed and Hisashi Harada and David A. Gewirtz},
journal = {Molecular Oncology},
year = {2020},
doi = {10.1002/1878-0261.12761},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Advanced Functional Materials 2025
Open access · OA
A One‐Two Punch Strategy Against Cancer: Simultaneously Inducing and Eliminating Senescent Tumor Cells
International Journal of Molecular Sciences 2022
Open access · CC-BY
Senescence of Tumor Cells in Anticancer Therapy—Beneficial and Detrimental Effects
JNCI Journal of the National Cancer Institute 2021
Open access · CC-BY
Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy
Signal Transduction and Targeted Therapy 2020
Open access · CC-BY
Overcoming cancer therapeutic bottleneck by drug repurposing
Molecular Cancer 2025
Open access · CC-BY
The controversial role of senescence-associated secretory phenotype (SASP) in cancer therapy
JNCI Journal of the National Cancer Institute 2010
Open access · OA